



Lilly Cares® Foundation 2023 State-Level Results

Diabetes Medications		
BAQSIMI® (glucagon) nasal powder; Basaglar® (insulin glargine injection); Glucagon™ (glucagon for injection); Humalog® (insulin lispro injection); Humulin® (human insulin); Lyumjev® (insulin lispro-aabc) injection; Trulicity® (dulaglutide) injection		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$510,000	56
AL	\$41,900,000	4149
AR	\$12,800,000	1093
AZ	\$20,300,000	1785
CA	\$45,400,000	4098
CO	\$12,300,000	1036
CT	\$6,200,000	565
DC	\$260,000	27
DE	\$4,800,000	407
FL	\$84,600,000	8005
GA	\$65,000,000	6532
HI	\$910,000	79
IA	\$13,700,000	1126
ID	\$12,100,000	1061
IL	\$45,600,000	3766
IN	\$79,600,000	6497
KS	\$25,300,000	2280
KY	\$29,800,000	2576
LA	\$27,800,000	2434
MA	\$20,200,000	1576
MD	\$23,300,000	2079
ME	\$9,600,000	836
MI	\$85,300,000	6656
MN	\$26,500,000	2163
MO	\$45,900,000	3865
MS	\$18,300,000	1689
MT	\$5,200,000	451
NC	\$103,800,000	9671
ND	\$2,700,000	220
NE	\$17,700,000	1559
NH	\$9,600,000	779
NJ	\$17,300,000	1657
NM	\$4,800,000	445
NV	\$10,400,000	903
NY	\$38,700,000	3574
OH	\$111,500,000	9022
OK	\$24,600,000	2264
OR	\$15,700,000	1287
PA	\$69,800,000	5841
PR	\$360,000	39
RI	\$7,800,000	614
SC	\$33,400,000	3028
SD	\$4,400,000	392
TN	\$63,000,000	5566
TX	\$185,000,000	18048
UT	\$17,800,000	1545
VA	\$56,700,000	5593
VI	\$39,000	4
VT	\$1,100,000	92
WA	\$20,800,000	1773
WI	\$46,800,000	3707
WV	\$15,100,000	1255
WY	\$3,300,000	327

Basaglar®, Humalog®, Humulin®, Lyumjev® and Trulicity® are registered trademarks and Glucagon™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. BAQSIMI® and Zyprexa® are registered trademarks of their respective owners.



Lilly Cares® Foundation 2023 State-Level Results

Mental Health Medications		
Cymbalta® (duloxetine delayed-release capsules); Prozac® (fluoxetine); Strattera® (atomoxetine); Symbyax® (olanzapine and fluoxetine); Zyprexa® (olanzapine)		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$1,000	1
AL	\$3,700,000	719
AR	\$120,000	26
AZ	\$81,000	16
CA	\$440,000	69
CO	\$120,000	23
CT	\$35,000	4
DE	\$70,000	9
FL	\$2,900,000	666
GA	\$7,100,000	1137
IA	\$120,000	18
ID	\$140,000	33
IL	\$350,000	59
IN	\$1,300,000	254
KS	\$1,800,000	301
KY	\$470,000	107
LA	\$370,000	77
MA	\$100,000	20
MD	\$330,000	60
ME	\$290,000	59
MI	\$500,000	96
MN	\$340,000	66
MO	\$1,200,000	213
MS	\$1,200,000	206
MT	\$250,000	38
NC	\$9,000,000	1421
ND	\$76,000	14
NE	\$420,000	76
NH	\$250,000	40
NJ	\$200,000	32
NM	\$35,000	9
NV	\$34,000	7
NY	\$300,000	44
OH	\$920,000	174
OK	\$1,300,000	241
OR	\$280,000	47
PA	\$1,100,000	185
RI	\$57,000	13
SC	\$690,000	147
SD	\$1,500,000	226
TN	\$2,500,000	398
TX	\$41,600,000	6420
UT	\$160,000	25
VA	\$4,400,000	763
WA	\$270,000	47
WI	\$400,000	70
WV	\$360,000	86
WY	\$260,000	61

Cymbalta®, Prozac®, Strattera®, and Symbyax® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. BAQSIMI® and Zyprexa® are registered trademarks of their respective owners.



Lilly Cares® Foundation 2023 State-Level Results

Cancer Medications		
Alimta® (pemetrexed for injection); Cyramza® (ramucirumab) injection; Erbitux® (cetuximab) injection; Jaypirca® (pirtobrutinib); Retevmo® (selpercatinib); Verzenio® (abemaciclib)		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$700,000	12
AL	\$13,900,000	181
AR	\$8,300,000	120
AZ	\$25,900,000	283
CA	\$56,300,000	622
CO	\$19,600,000	207
CT	\$11,900,000	111
DC	\$350,000	3
DE	\$1,800,000	19
FL	\$87,800,000	951
GA	\$30,500,000	352
HI	\$2,000,000	22
IA	\$8,800,000	106
ID	\$5,200,000	60
IL	\$31,600,000	332
IN	\$20,900,000	211
KS	\$9,700,000	108
KY	\$9,400,000	104
LA	\$9,300,000	97
MA	\$12,600,000	131
MD	\$17,000,000	169
ME	\$5,500,000	59
MI	\$22,400,000	239
MN	\$19,200,000	209
MO	\$20,800,000	209
MS	\$10,200,000	116
MT	\$2,500,000	34
NC	\$33,800,000	395
ND	\$1,600,000	18
NE	\$6,100,000	70
NH	\$3,900,000	43
NJ	\$31,500,000	331
NM	\$2,800,000	32
NV	\$9,000,000	101
NY	\$39,000,000	405
OH	\$46,000,000	490
OK	\$8,200,000	105
OR	\$15,300,000	153
PA	\$38,300,000	385
PR	\$1,600,000	12
RI	\$3,700,000	35
SC	\$12,800,000	194
SD	\$1,900,000	24
TN	\$22,200,000	273
TX	\$123,900,000	1368
UT	\$9,200,000	88
VA	\$24,300,000	303
VI	\$210,000	1
VT	\$2,100,000	18
WA	\$22,000,000	233
WI	\$21,500,000	224
WV	\$6,100,000	78
WY	\$1,000,000	18

Alimta®, Cyramza®, Erbitux®, Jaypirca®, Retevmo® and Verzenio® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.



Lilly Cares® Foundation 2023 State-Level Results

Other Medications		
Cialis® (tadalafil); Emgality® (galcanezumab-gnlm injection); Evista® (raloxifene hydrochloride); Forteo® (teriparatide injection); Humatrope® (somatropin) for injection; Olumiant® (baricitinib); REYVOW® (lasmiditan); Taltz® (ixekizumab) injection		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$1,100,000	23
AL	\$28,500,000	784
AR	\$35,200,000	592
AZ	\$21,800,000	534
CA	\$65,200,000	1437
CO	\$18,900,000	471
CT	\$8,100,000	179
DC	\$240,000	3
DE	\$4,100,000	87
FL	\$118,800,000	3329
GA	\$56,800,000	1359
HI	\$3,500,000	59
IA	\$11,700,000	301
ID	\$16,500,000	348
IL	\$35,400,000	801
IN	\$46,100,000	997
KS	\$14,300,000	335
KY	\$17,500,000	490
LA	\$25,100,000	525
MA	\$17,800,000	352
MD	\$10,700,000	262
ME	\$6,600,000	124
MI	\$40,100,000	893
MN	\$23,400,000	491
MO	\$37,000,000	873
MS	\$10,900,000	374
MT	\$5,100,000	133
NC	\$53,800,000	1470
ND	\$3,700,000	87
NE	\$7,900,000	189
NH	\$5,500,000	152
NJ	\$30,400,000	580
NM	\$6,000,000	132
NV	\$7,600,000	175
NY	\$39,500,000	873
OH	\$56,100,000	1191
OK	\$21,700,000	460
OR	\$13,700,000	288
PA	\$44,100,000	1095
PR	\$3,000,000	63
RI	\$3,700,000	71
SC	\$24,200,000	591
SD	\$5,400,000	149
TN	\$38,000,000	897
TX	\$130,600,000	2972
UT	\$12,600,000	271
VA	\$27,800,000	703
VT	\$1,400,000	34
WA	\$24,700,000	521
WI	\$26,300,000	658
WV	\$7,800,000	196
WY	\$2,000,000	69

Cialis®, Emgality®, Evista®, Forteo®, Humatrope®, Olumiant®, REYVOW® and Taltz® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.